Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at the time of the randomization:~Key Inclusion Criteria:~* Must have confirmed diagnosis of RRMS according to McDonald criteria #1-4~* Must have a baseline EDSS between 0.0 and 5.0, inclusive.~* Must have relapsing-remitting disease course.~Key Exclusion Criteria:~* Other chronic disease of immune system, malignancies, urologic, pulmonary, gastrointestinal disease~* Pregnant or nursing women~Note: Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- BG00012 240 mg Twice Daily (BID) (Type: EXPERIMENTAL): Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
- BG00012 240 mg 3 Times Daily (TID) (Type: EXPERIMENTAL): Participants received two 120 mg BG00012 capsules orally three times daily (TID)
- Placebo (Type: PLACEBO_COMPARATOR): Participants received two placebo capsules orally three times daily (TID)
- Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD) (Type: ACTIVE_COMPARATOR): Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).